Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are up 2.2% to trade at $7.06 at last check. The company announced last week it filed a Biologics License Application with the U.S. Food and Drug Administration (FDA) for isidolimab, its antibody-based treatment for patients with pustular psoriasis.The stock is extending last week's move above the $7 level, and marked a fresh two-year high of $7.25 right out of the gate. VNDA toppled resistance at $5.50 earlier this month after spending November firmly below t ...